Early relapse of follicular lymphoma may increase risk of death
the ONA take:
Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients, according to a new study published online ahead of print in the Journal of Clinical Oncology.
Researchers at the University of Rochester in New York and colleagues analyzed data from the National LymphoCare Study in order to evaluate whether patients with follicular lymphoma who experience progression of disease within 2 years of initial R-CHOP therapy have an increased risk of death.
Results showed that the 5-year overall survival was 50% for those who experienced early progression of disease compared with 90% among those who did not.
"Through research we have confirmed that all relapsed patients are not equal, and therefore should not be approached the same at diagnosis nor at the time of relapse in terms of therapies," Carla Casulo, MD, oncologist and assistant professor of Medicine at the University of Rochester said.
Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
- Evidenced-Based Radiation Treatment Tied to Cost Savings in Early Stage Breast Cancer
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|